Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Laken (Brussel), Belgium Clinical Trials

A listing of Laken (Brussel), Belgium clinical trials actively recruiting patients volunteers.

RESULTS

Found (10) clinical trials

RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID

The IVAC WAREHOUSE concept is based on RNA drug products shelved in a warehouse and targeting shared tumour-associated antigens (TAAs). The BioNTech Group (henceforward the "company") has identified a set of target antigens commonly expressed in TNBC. The selected breast cancer-associated antigens have been shown by immunogenicity testing to constitute ...

Phase

1.02 miles

Learn More »

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

This is an open label, multicenter, dose escalation, phase Ib study to determine the recommended phase II dose (RP2D), by assessing the maximum tolerated dose (MTD), safety and preliminary efficacy of selinexor in adult patients with relapsed/refractory B-cell malignancies receiving either R-DHAOx (Group A) or R-GDP (Group B). This dose ...

Phase

1.86 miles

Learn More »

BI 894999 First in Human Dose Finding Study in Advanced Malignancies

The aim of the phase Ia (dose escalation) part of this trial is to assess the Maximum Tolerated Dose (MTD) of BI 894999 administered at escalating doses in two treatment schedules (schedule A of continuous dosing, schedule B with two weeks on treatment followed by one week off in 3-week ...

Phase

2.38 miles

Learn More »

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group expansion in selected solid tumor indications. The current trial is composed of a standard dose escalation "3 + 3" cohort design, for which 3 to 6 subjects will be enrolled at each dose level depending on the occurrence of ...

Phase

2.38 miles

Learn More »

A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

This Phase 1, open-label, multicenter, global study will evaluate the safety, pharmacokinetics, and activity of emactuzumab and atezolizumab administered in combination in participants with selected locally advanced or metastatic solid tumors that are not amenable to standard treatment. Participants who receive emactuzumab and atezolizumab will continue to receive study drug ...

Phase

3.7 miles

Learn More »

Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia

This trial is designed as an open label, non randomised, dose escalation and cohort expansion, first administration to human study to be conducted in approximately 20 European sites. The study is aiming to identify the Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD), to assess the pharmacokinetics and to ...

Phase

3.7 miles

Learn More »

Study Evaluating the Safety Pharmacokinetics (PK) Pharmacodynamics (PD) and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

This open-label, two-part study is designed to assess the safety, PK, PD, and therapeutic activity of Selicrelumab in combination with vanucizumab or bevacizumab in participants with metastatic solid tumors not amenable to standard treatment. Part I (dose escalation) is designed to establish the maximum tolerated dose (MTD) of Selicrelumab in ...

Phase

3.7 miles

Learn More »

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single agent and in combination with either LEE011 or BYL719 in adult patients with locally advanced or metastatic ER+ breast cancer who have progressed after ...

Phase

3.7 miles

Learn More »

SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias

Cerebellar ataxias (CA) and spastic paraplegias (SP) are genetically and clinically very heterogeneous. More than 40 loci are already known but the number of phenotypes is even greater suggesting further genetic heterogeneity. These progressive disorders are often severe and fatal, due to the absence of specific therapy. The SPATAX network ...

Phase

4.42 miles

Learn More »

A Trial of TAS-114 in Combination With S-1

This is an open-label, non-randomized, dose-escalation Phase I study of TAS-114 administered in combination with S-1, evaluating the safety, tolerability, pharmacokinetics and preliminary antitumor activity of the TAS-114/S-1 regimen in patients with advanced solid tumors. The study will be conducted in two parts: a Dose-Escalation Phase (Part 1) to determine ...

Phase

4.42 miles

Learn More »